Medtronic (NYSE:MDT) Stock Price Up 0% - Here's Why

Shares of Medtronic plc (NYSE:MDT - Get Free Report) were up 0% during mid-day trading on Tuesday . The company traded as high as $88.70 and last traded at $88.10. Approximately 1,514,745 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 7,875,320 shares. The stock had previously closed at $88.08.

Analysts Set New Price Targets

Several research firms have recently weighed in on MDT. Truist Financial reduced their price objective on Medtronic from $93.00 to $89.00 and set a "hold" rating on the stock in a research note on Wednesday, December 18th. Barclays lifted their price target on Medtronic from $105.00 to $109.00 and gave the company an "overweight" rating in a report on Tuesday, November 26th. Evercore ISI upped their price objective on Medtronic from $100.00 to $104.00 and gave the company an "outperform" rating in a report on Tuesday, October 1st. Wells Fargo & Company reduced their price objective on Medtronic from $106.00 to $98.00 and set an "overweight" rating for the company in a research note on Wednesday, November 20th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Medtronic from $99.00 to $96.00 and set a "neutral" rating for the company in a report on Friday, November 15th. One analyst has rated the stock with a sell rating, nine have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $95.00.

Medtronic Stock Performance

The company has a market cap of $113.03 billion, a P/E ratio of 26.96, a price-to-earnings-growth ratio of 2.49 and a beta of 0.83. The company has a current ratio of 1.84, a quick ratio of 1.39 and a debt-to-equity ratio of 0.51. The company has a 50 day moving average price of $83.64 and a 200-day moving average price of $85.29.

Medtronic (NYSE:MDT - Get Free Report) last posted its quarterly earnings data on Tuesday, November 19th. The medical technology company reported $1.26 EPS for the quarter, beating analysts' consensus estimates of $1.25 by $0.01. The company had revenue of $8.40 billion for the quarter, compared to analyst estimates of $8.27 billion. Medtronic had a net margin of 13.00% and a return on equity of 13.79%. The company's quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.25 EPS. On average, equities analysts expect that Medtronic plc will post 5.45 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 10th. Shareholders of record on Friday, December 27th were given a $0.70 dividend. The ex-dividend date was Friday, December 27th. This represents a $2.80 annualized dividend and a yield of 3.18%. Medtronic's dividend payout ratio is currently 85.63%.

Insider Buying and Selling

In related news, EVP Brett A. Wall sold 9,850 shares of the business's stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $80.41, for a total transaction of $792,038.50. Following the completion of the transaction, the executive vice president now owns 40,708 shares of the company's stock, valued at approximately $3,273,330.28. The trade was a 19.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Medtronic

A number of large investors have recently added to or reduced their stakes in the business. Flagship Harbor Advisors LLC raised its holdings in Medtronic by 33.2% in the 4th quarter. Flagship Harbor Advisors LLC now owns 10,594 shares of the medical technology company's stock worth $846,000 after purchasing an additional 2,638 shares in the last quarter. Insight Inv LLC grew its position in shares of Medtronic by 4.9% in the 4th quarter. Insight Inv LLC now owns 14,906 shares of the medical technology company's stock worth $1,191,000 after buying an additional 698 shares during the period. Advocate Group LLC grew its position in shares of Medtronic by 4.8% in the 4th quarter. Advocate Group LLC now owns 106,776 shares of the medical technology company's stock worth $8,529,000 after buying an additional 4,897 shares during the period. Vantage Wealth lifted its position in Medtronic by 9.1% during the 4th quarter. Vantage Wealth now owns 226,315 shares of the medical technology company's stock valued at $18,078,000 after acquiring an additional 18,800 shares during the period. Finally, Toth Financial Advisory Corp lifted its holdings in shares of Medtronic by 9.1% during the fourth quarter. Toth Financial Advisory Corp now owns 59,878 shares of the medical technology company's stock valued at $4,783,000 after purchasing an additional 5,015 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company's stock.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.